Axsome Therapeutics

1. solriamfetol ENGAGE Ph3 topline4Q 2026solriamfetol ENGAGE Ph3 topline, 4Q 2026, major
2. AUVELITY corporate updateNov 2026AUVELITY corporate update, Nov 2026, notable
3. solriamfetol SUSTAIN Ph3 topline2027solriamfetol SUSTAIN Ph3 topline, 2027, major
4. Ecopipam Teva PDUFA date1Q 2027Ecopipam Teva PDUFA date, 1Q 2027, material
5. Cytisinicline Achieve FDA decision1H 2027Cytisinicline Achieve FDA decision, 1H 2027, material
6. AXS-12 reboxetine PDUFA dateMay 1, 2027AXS-12 reboxetine PDUFA date, May 1, 2027, major
7. Blackstone delayed-draw term loan financingMay 31, 2027Blackstone delayed-draw term loan financing, May 31, 2027, routine
8. SYMBRAVO corporate updateJan–Feb 2028SYMBRAVO corporate update, Jan–Feb 2028, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.